CompletedNCT00796432

A Study of Dopamine Type 2 (D2) Receptor Occupancy Following a Single Oral Dose of OROS Paliperidone

Medication studyAges 20–45Schizophrenia

The study in practice

Understand this study

This study was for healthy volunteers. Listed age limits: 20 years to 45 years. Other eligibility criteria applied.

Study clarity

Study start dateMarch 2003

Recruitment status: Completed
Enrollment listed in the registry: 4
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Sponsor type: Pharmaceutical company
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 1
Locations: Not clearly listed
Age range: From 20 Years to 45 Years
Official registry ID: NCT00796432
Official title: Show the full official title
Open-label Positron Emission Tomography (PET) Study of Central D2-receptor Occupancy in Healthy Subjects Following a Single Oral Dose of OROS Paliperidone

Completed

Locations not listed

FAQ

Who is behind this study?

The study sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including OROS paliperidone.

Who was this study for?

This study was for healthy volunteers. Listed age limits: 20 years to 45 years. Other eligibility criteria applied.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.